For more than half a century, metabolic perturbations have been explored in the failing myocardium, highlighting a reversion to a more fetal-like metabolic profile (characterized by depressed fatty acid oxidation and concomitant increased reliance on use of glucose). More recently, alterations in ketone body and amino acid/protein metabolism have been described during heart failure, as well as mitochondrial dysfunction and perturbed metabolic signaling I n order to meet the exceptionally high metabolic demands of continuous contractility, the heart catabolizes an array of substrates. Indeed, the heart has been termed a "metabolic omnivore," capable of consuming fatty acids (FAs), glucose, ketone bodies, and amino acids (AA) for the replenishment of ATP. Central to achievement of this goal is metabolic flexibility, wherein the heart shifts reliance from one substrate to another, in response to acute perturbations in workload and/or substrate availability (including feeding-fasting and sleep-wake cycles, which occur on a daily basis). The importance of metabolic flexibility is underscored by appreciation for the fact that various substrates are more than just a fuel for the heart, serving also as building blocks for numerous cellular components (e.g., membranes, proteins), cofactors, and signaling molecules. 
SUMMARY
For more than half a century, metabolic perturbations have been explored in the failing myocardium, highlighting a reversion to a more fetal-like metabolic profile (characterized by depressed fatty acid oxidation and concomitant increased reliance on use of glucose). More recently, alterations in ketone body and amino acid/protein metabolism have been described during heart failure, as well as mitochondrial dysfunction and perturbed metabolic signaling I n order to meet the exceptionally high metabolic demands of continuous contractility, the heart catabolizes an array of substrates. Indeed, the heart has been termed a "metabolic omnivore," capable of consuming fatty acids (FAs), glucose, ketone bodies, and amino acids (AA) for the replenishment of ATP. Central to achievement of this goal is metabolic flexibility, wherein the heart shifts reliance from one substrate to another, in response to acute perturbations in workload and/or substrate availability (including feeding-fasting and sleep-wake cycles, which occur on a daily basis). The importance of metabolic flexibility is underscored by appreciation for the fact that various substrates are more than just a fuel for the heart, serving also as building blocks for numerous cellular components (e.g., membranes, proteins), cofactors, and signaling molecules.
During various disease states, particularly heart failure (HF), cardiac metabolism is perturbed in a chronic manner, resulting in metabolic inflexibility. Thus, HF is characterized by relatively permanent and predictable shifts in metabolism, associated with impaired signaling (e.g., Ca homeostasis and ROS signaling, the reader is directed to the papers by Brown and Griendling (1) and Bers (2) .
CONTRIBUTIONS OF INDIVIDUAL SUBSTRATES
FATTY ACID METABOLISM. Fatty acid oxidation (FAO) represents a significant fuel source for the myocardium, providing an estimated 50% to 70% of the ATP consumed during contraction (3) . In comparison with carbohydrate use, rates of cardiac FAO are relatively unaffected by acute changes in workload or energy demand (4, 5) . Cardiac FAO typically exhibits greater flexibility following changes in substrate availability (6) . Such observations could indicate that FAO maintains baseline energy needs of the heart while matching rates of FA uptake with oxidation. If true, then cardiac FAO deficits could potentially precipitate contractile dysfunction through energy impairment and/or diversion of excess FAs into signaling and/or "lipotoxic" pathways.
This section reviews evidence supporting these concepts.
One of the most consistent metabolic perturbations during HF is decreased use of FA, which has been observed in both animal and human studies (7) (8) (9) (10) (11) . In doing so, the failing heart reverts to a fetal-like metabolic program, reflected by a repression of various genes encoding core FAO pathway proteins (e.g., medium chain acyl-coenzyme A [CoA] dehydrogenase, beta-hydroxyacyl-CoA dehydrogenase) and their upstream regulators (e.g., PPAR-a, RXR-a, PGC-1a) (12,13). It has been proposed that, acutely, this metabolic perturbation serves as an adaptation by promoting increased reliance on more energy-efficient fuels (in terms of ATP per oxygen molecule consumed), which may be particularly important in the setting of ischemic heart disease (14) . Consistent with this concept, attenuation of FAO is observed prior to the onset of contractile dysfunction (e.g., induced by pressure overload) (15) . However, this metabolic reprogramming causes chronic dyssynchrony between energy demand (which is increased), substrate availability (circulating FAs are typically increased), and use (i.e., FAO is decreased) during HF. In other words, a decrease in FAO rates could reduce ATP availability for contraction (if below the capacity of alternative compensating pathways) concomitant with increased diversion of FA species into signaling/lipotoxic pathways, culminating in impairment of contractility. Evidence in support of this concept includes reports of modest perturbations in markers of energy status in the failing myocardium, as well as accumulation of lipotoxic markers (16) (17) (18) . The latter, when elevated, can contribute to cell death and cardiac remodeling. dents calorie-dense high-fat diets has been shown to preserve and even improve contractility in distinct models of HF (including pressure overload, myocardial infarction, and hypertension), although not all studies report this benefit (perhaps due to differences in dietary composition, duration of feeding, and other factors) (29) (30) (31) (32) (33) . Observations such as these raise the question of whether cardiac FAO impairment primarily leads to energy deficiency as opposed to lipotoxicity and signaling imbalance. However, strategies designed to cause a mismatch between FA uptake and FAO (e.g., overexpression of FATP-1 or ACSL-1) invariably result in cardiomyopathy associated with markers of lipotoxicity (34, 35) . In addition, the failing heart is considered to be in a pro-lipotoxic environment (36) . Furthermore, haploinsufficiency of mCPT1 increases susceptibility to pressure overloadinduced cardiac dysfunction through lipotoxic Wende et al.
Metabolic Origins of Heart Failure J U N E 2 0 1 7 : 2 9 7 -3 1 0 pathways (37) . Similarly, germline VLCAD deletion increases cardiac lipotoxicity during high-fat feeding (38) . Collectively, these studies suggest that impaired cardiac FAO could lead to cardiac dysfunction not only through energy deficiency but also through lipotoxicity. and indirectly (i.e., acetylation and inhibition of pyruvate dehydrogenase, and therefore impairment of glucose oxidation) (40, 41) . It is noteworthy that cardiac FAO capacity is extremely high, such that enzymes involved in b-oxidation must be inhibited markedly in order to impact FAO flux. This is exemplified by VLCAD and CPT1b heterozygous knockout mouse hearts, which exhibit no baseline phenotype despite a 50% loss in enzymatic activity (21, 37) ; homozygous cardiomyocyte-specific knockout of VLCAD also has no significant effects on cardiac FAO rates, likely due to compensation by other acyl-CoA dehydrogenase isoforms (e.g., LCAD) (21) . In contrast, cardiac FAO is affected by cofactor availability (e.g., GLUCOSE METABOLISM. Use of cardiac glucose (i.e., glycolysis and glucose oxidation [GLOX]), is important for the developing (fetal) heart, during which time glucose delivery is high, and oxygen availability is relatively low (45) . Soon after birth, use of glucose decreases concomitant with increased dietary FA and oxygen delivery. However, the healthy adult heart has the capacity to increase reliance on use of glucose in response to both physiologic (e.g., exercise) and pathologic (e.g., ischemia) stresses. During HF, metabolic flexibility is lost, which may be due in part to cardiac insulin resistance (IR); complex alterations in insulin signaling within cardiomyocytes during HF have been reviewed recently (46) . It has been suggested that, under some conditions (e.g., hemodynamic stress), IR may actually protect the heart by reducing fuel toxicity (47) . However, as HF progresses, an uncoupling between glycolysis and GLOX ensues, potentially contributing to cellular dysfunction (48) . Interestingly, circulating glucose levels tend to be elevated during both acute and chronic HF.
For example, elevated serum glucose levels at the time of hospital admission for acute HF syndromes, independent of diabetes status, are associated with higher mortality (49, 50) . Chronically, HF is also associated with peripheral IR. Whether these perturbations in cardiac and/or whole-body glucose homeostasis contribute to the pathogenesis of HF is still under debate (46) . The purpose of this subsection ( Figure 1 ) is to review current knowledge regarding the use of glucose during HF; we will focus primarily on this independent of diabetes status, as the latter has been reviewed extensively elsewhere (51) (52) (53) .
Whether perturbations in use of cardiac glucose are adaptive or maladaptive during HF appears to depend on the underlying stress (i.e., ischemic versus nonischemic), as well as duration (i.e., acute versus chronic). In the context of hypertension-induced dilated cardiomyopathy, glucose use is increased, with a predominate augmentation of glucose uptake and glycolysis, and a concomitant uncoupling of glycolytic flux from GLOX (48, 54) . There is mounting evidence that the remodeling of glucose metabolism is one of the initial changes driving the heart to hypertrophy and could act as an early marker of disease progression (55) . Acutely enhancing glucose metabolism in the setting of ischemic injury and ventricular fibrillation may be protective (56, 57) . Conversely, cardiomyocyte-specific GLUT4 ablation decreased functional recovery in response to ischemic injury (66) . Although loss of GLUT8 has been explored in the context of diet-induced obesity (67), a direct role during HF remains to be explored. Studies of these transporters, as well as those of the other cardiac-enriched GLUTs (GLUT3, GLUT10, and GLUT12) will continue to provide crucial insight into the contribution of glucose uptake and metabolism during the progression of HF.
An emerging area has focused on non-GLUTmediated glucose transport through the sodiumglucose cotransporters (SGLT), especially given that empagliflozin (an SGLT2 inhibitor) decreased HF incidence in diabetic patients (68) . The mechanism of this protection is likely multifaceted, including lowering of both glucose and sodium, as well as influences on glomerular filtration and the cardiorenal axis (69) .
Interestingly, SGLT1 is induced in the heart during both diabetic and ischemic cardiomyopathy (70) , and phlorizin (another SGLT inhibitor) decreased cardiac glucose uptake and directly affected tolerance of the heart to ischemia (71) . Future studies will undoubtedly reveal important insights regarding the effects of SGLT inhibitors on cardiac metabolism and protection.
P o l y o l p a t h w a y . Augmented glucose uptake and glycolytic flux, particularly when in excess of GLOX, Increased glucose uptake channels carbon into the polyol, PPP, and HBP pathways; this likely contributes to mitochondrial dysfunction, genetic reprogramming, and impaired calcium handling during heart failure. HBP ¼ hexosamine biosynthesis; PPP ¼ pentose phosphate pathway; ROS ¼ reactive oxygen species.
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enhances diverting of glucose moieties into signaling pathways. This includes the polyol pathway.
Although primarily implicated in diabetic complications, overexpression of aldose reductase, the first step in this pathway, results in an age-related decline in heart function and exacerbated ischemic injury (72) . Further studies are warranted in order to elucidate fully the importance of the polyol pathway in the pathogenesis of HF. 
P e n t o s
e p h o s p h a t e p a t h w a y .
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Wende et al. Elevated levels of b-OHB during heart failure provide excess acetyl-CoA for acetylation reactions and inhibit deacetylation at the same time.
Increased ketone bodies also likely compete for the oxidation of fatty acids and glucose and potentially activate cell surface receptors.
CoA ¼ coenzyme A.
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Metabolic Origins of Heart Failure During heart failure, intracardiac branched chain amino acids are increased while taurine levels are decreased, leading to impairments in autophagy, mitochondrial function, and calcium homeostasis. BCAA ¼ branched-chain amino acids; BCKA ¼ branched chain alpha-keto acids;
LAT ¼ large neutral amino acid transporter; mTOR ¼ mammalian target of rapamycin; TauT ¼ taurine transporter; TCA ¼ tricarboxylic acid. The ubiquitin proteasome system also plays a critical role in protein turnover. Accumulation of ubiquitinated proteins has been consistently observed across studies investigating human HF samples (123, 125, 130, 131) . This accumulation could result from an imbalance between the activity of ubiquitin ligases, de-ubiquitinating enzymes, and the proteasome. In the last case, studies assessing proteasome activity have produced inconsistent results.
Metabolic Origins of Heart Failure J U N E 2 0 1 7 : 2 9 7 -3 1 0 CoA ¼ coenzyme A; FA ¼ fatty acid; FAO ¼ fatty acid oxidation; KB ¼ ketone body; mTOR ¼ mammalian target of rapamycin.
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Metabolic Origins of Heart Failure J U N E 2 0 1 7 : 2 9 7 -3 1 0 mechanisms designed to promote cardiomyocyte substrate uptake in the face of energy deficit (e.g., AMPK activation promoting GLUT1/4 and CD36 translocation for glucose and FA uptake, respectively). Importantly, during diabetes, dyssynchrony between fuel availability and use will be amplified further, due to greater levels of circulating FAs, ketone bodies, glucose, and BCAAs. In other words, the failing myocardium can be considered an engine flooded with fuel.
CONCLUSIONS According to the model described above (Central 
